SGLT-2抑制剂治疗2型糖尿病患者的管理策略:有效安全处方之道
本文为临床病例导向的文章,讨论使用SGLT-2抑制剂治疗2型糖尿病时如何实现有效且安全的处方。文章总结了最新进展,涉及泌尿生殖道感染风险及减轻策略、糖尿病酮症酸中毒的避免策略,以及SGLT-2抑制剂相关红细胞增多症这一新的上市后观察,旨在帮助临床医生更自信地使用格列净类药物。
要点
- SGLT-2抑制剂可改善2型糖尿病患者心血管和肾脏结局,但处方仍不足。
- 泌尿生殖道感染和糖尿病酮症酸中毒是可管理的安全性问题,已有减轻策略。
- 新观察提示SGLT-2抑制剂可能引起红细胞增多症,需关注其心血管影响。
核心结论
- SGLT-2抑制剂在2型糖尿病中具有心血管和肾脏获益,但处方不足,需克服对急性不良反应的担忧。
研究设计与样本
- 临床病例导向的文章,讨论并总结SGLT-2抑制剂有效安全处方的最新进展。
主要发现
- SGLT-2抑制剂可改善2型糖尿病患者心血管和肾脏结局,但在初级保健和专科门诊中处方仍不足。
- 提供者担心泌尿生殖道感染风险增加和糖尿病酮症酸中毒发生,阻碍了更广泛使用。
- 近年有专家提出可减轻感染风险的有效策略,避免糖尿病酮症酸中毒的策略知识也在增长。
- 多个团队过去几年的上市后观察提示SGLT-2抑制剂可引起红细胞增多症,可能对心血管健康产生不利影响。
临床怎么用
- 临床医生应了解减轻泌尿生殖道感染和避免糖尿病酮症酸中毒的策略,以更自信地处方SGLT-2抑制剂。
- 处方SGLT-2抑制剂时需关注红细胞增多症这一新报告的不良反应及其潜在心血管影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium glucose cotransporter-2 (SGLT-2) inhibitors are shown to improve cardiovascular and renal outcomes in people with type 2 diabetes, and their use in primary care and subspecialty clinics continues to grow. However, their prescription remains underused. One of the obstacles precluding wider use of these agents is providers' fear of causing more likely immediate side effects over waiting for improvements in morbidity and mortality that are accrued with chronic SGLT-2 inhibitor prescription. One of the concerns is an increased risk of genitourinary infections. Recently, several effective strategies were suggested by the experts that can be used to mitigate the infection risk. Another barrier is development of diabetic ketoacidosis. Fortunately, there is a growing body of knowledge for strategies that may help avoid diabetic ketoacidosis. Finally, a novel postmarketing observation reported by several groups over the past few years suggested that SGLT-2 inhibitor can cause erythrocytosis, which paradoxically can detrimentally impact cardiovascular health. This clinical case-based article will discuss and summarize newest developments in the field and allow practitioners to become more confident in using gliflozin therapy.
引用
- Gosmanov AR. Approach to the patient with type 2 diabetes treated with SGLT-2 inhibitor: art of effective and safe prescription. J Clin Endocrinol Metab. 2026. PMID: 41433343. doi:10.1210/clinem/dgaf690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。